The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Azacitidine Celgene

25 milligram(s)/millilitre Powder for suspension for injection

Celgene Europe B.V.EU/1/19/1382/001

Main Information

Trade NameAzacitidine Celgene
Active SubstancesAzacitidine
Strength25 milligram(s)/millilitre
Dosage FormPowder for suspension for injection
Licence HolderCelgene Europe B.V.
Licence NumberEU/1/19/1382/001

Group Information

ATC CodeL01BC07 azacitidine


Licence Issued02/09/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription. (See Annex I: Summary of Product Characteristics, 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back